Virtual Clinical Trials Market

Market Size

The global virtual clinical trials market, valued at $12.9 billion in 2025, is projected to reach $13.6 billion in 2026 and $30.5 billion by 2035, representing a CAGR of 9.4% during the forecast period 2026 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of study, the interventional segment holds the highest share (75%) of the market.
• With regards to mode of virtual clinical trials, the hybrid clinical trials segment dominates the global market.
• Based on the therapeutic area, the oncological disorders segment holds the largest market share (nearly 15%) in 2026.
• With respect to clinical trial phase, Phase II virtual clinical trials capture the highest share (~40%) in 2026.
• Based on end users, pharmaceutical and biotechnology companies hold a larger share (~55%) within the virtual clinical trial market.
• In terms of geographical regions, North America captures the majority of the market share. Notably, Asia-Pacific is anticipated to grow at a faster pace in the near future.

Market Overview

Clinical trials are prospective biomedical research studies designed to evaluate medical, surgical or behavioral interventions in patients and investigate novel approaches for the diagnosis, prevention and treatment of diseases. These trials are essential to advance overall medical knowledge and improve the patient experience by minimizing the adverse effects associated with a clinical intervention (drug, device, vaccine or procedure).

However, clinical trials are prone to significant delays, primarily due to various constraints, such as insufficient patient recruitment, inefficient study protocols and low patient retention. Such delays significantly increase the cost associated with clinical trials, thereby making it difficult for the sponsors to complete the study.

Interestingly, more than $2 billion capital investment is required to complete the overall drug development process, and majority of these funds are utilized in clinical research only. Owing to the losses incurred due to study delays, stakeholders engaged in clinical research are actively seeking new and efficient approaches for conducting clinical trials.

In this context, virtual / decentralized clinical trials have emerged as an effective approach, being adopted by several pharmaceutical and biotechnology companies, as they offer enhanced patient access, improved retention rates, real-time data collection, cost-effectiveness, increased data quality, faster recruitment and resilience towards external factors impacting clinical research.

In virtual clinical trials assessment, patients can participate in the trial through local labs and healthcare sites or even their homes, minimizing / completely eliminating the need for traditional brick-and-mortar trial sites. Moreover, this approach of clinical trial utilizes several virtual techniques such as telemedicine, sensory-based technologies, wearable medical devices, home visits and patient-driven virtual health care interfaces in order to facilitate a smooth conduct of the clinical trials. Interestingly, as per a tufts study, adopting such approaches and solutions allows sponsors to save up to 5 to 14 times the overall cost associated with phase II and phase III studies.

Science 37 played a crucial role in helping GSK enroll patients for a phase III clinical trial for its drug linerixibat for treatment of cholestatic pruritus in primary biliary cholangitis (PBC) patients. The company’s direct-to-participant site solution helped enroll nearly half of the US participants.

With growing awareness about the advantages of virtual clinical trials, researchers and healthcare professionals are actively adopting virtual mode of trials, offering significant opportunities for several service / platform providers in the coming years.

Market Trends

• Increasing Partnerships: The growing interest of pharmaceutical and biotechnology companies in conducting virtual clinical trials is evident from the rise in partnership activity in the market. Of all the deals signed in the current year, majority were platform / technology utilization agreements.
• Funding Activity: A cumulative amount of around USD 5 billion has been raised by players engaged in the virtual clinical trials domain, since 2019. This is reflective of the growing interest of players towards adoption decentralized mode of clinical trials, worldwide. It is worth noting that in terms of the funding amount raised, Novotech raised the maximum funding amount worth USD 990 million.

Industry Experts

The virtual clinical trials market report features detailed transcripts of interviews held with the industry stakeholders (arranged in decreasing order of seniority level):

• Chief Executive Officer and Founder, Small Company, Belgium
• Chief Executive Officer and Founder, Small Company, Australia
• Former Chief Executive Officer and President, Small Company, US
• Chairman, Large Company, US
• Chief Innovation Officer and President, Mid-sized Company, US
• Chief Strategy Officer, Small Company, US
• Former Chief Commercial Officer, Vice President Global Head of Chief Technology and Strategy, Former Chief Delivery Officer, Former Head of Marketing, Large Company, US
• Former Executive Director, Small Company, US
• Head of Operations, Small Company, Bulgaria
• Former Key Account Director, Mid-sized Company, Germany
• Senior Business Development Director, Small Company, Singapore
• Former Senior Manager Business Development, Mid-sized Company, UK
• Former Business Development Manager, Mid-sized Company, UK

Market Share Insights

Market Share by Type of Study

• Currently, interventional studies occupy the largest market share (~75%). This can be attributed to the fact that these studies help in determining the actual cause and effect relationship between the intervention and patient outcomes, which is essential to examine the efficacy and safety of an intervention.
• The market for observational studies is estimated to grow at a higher CAGR of around 13% in the coming decade.

Market Share by Therapeutic Area

• The oncological disorders segment holds the majority share (~15%) of virtual / decentralized clinical trials market in 2026. Further, the market for oncological disorders is anticipated to grow at a higher annualized rate (CAGR) of nearly 12% during the forecast period.
• This is because patients suffering from oncological disorders go through several intensive treatments, due to which they face several physical and psychological side effects. Owing to the ill effects, it gets difficult for the patients to reach the trial location, ultimately making them drop out of the study.
• These challenges associated with the traditional mode of conducting trials for oncological interventions have prompted stakeholders to adopt a decentralized approach for conducting their trials efficiently.

Market Share by End User

• Pharmaceutical and biotechnology companies capture a larger share (~55%) within the market. This can be attributed to the fact that virtual clinical trials are cost-effective and they improve patient enrolment and retention, enabling pharmaceutical and biotechnology companies to swiftly conduct research on new drugs.
• As per virtual clinical trials market forecast, clinical research organizations segment will observe CAGR of ~10% during the forecast period.

Market Share by Geographical Regions

• It is worth highlighting that North America captures majority of the current total virtual trials market size by region.
• The market in Asia-Pacific is expected to grow at a faster pace during the forecast period. This can be attributed to the fact that Asian countries, including China, Japan and Korea have a higher adoption rate of novel technologies that are being used in virtual clinical trials.
• The detailed methodology across the global virtual clinical trials market and revenue generated across various segments is available in the full report.

Key Market Insights

Competitive Landscape: Virtual Clinical Trials Market

The market landscape is concentrated with the presence of over 140 players engaged in providing services / platforms for conducting virtual clinical trials. Notably, nearly 30% of the virtual clinical trial companies were established post-2015, indicating significant start-up activity in the virtual clinical trials industry. Examples of service / platform providers (established post-2022, in alphabetical order) include Fortrea (Spin-off of LabCorp), Health Studio and Zealth.

Notably, around 85% of the players are offering platforms for a smooth conduct of virtual clinical trials. These digital platforms help healthcare professionals to efficiently monitor the patients and gather data associated with the trial. Further, these platforms also play a crucial role in ensuring patient engagement, real-time communication with patients and improving trial efficiency. Notable examples of such service / platform providers (in alphabetical order) include Capgemini, Curebase, Huma, IQVIA and WeGuide.

Leading Companies Providing Virtual Clinical Trial Services

Examples of key players involved in the industry (which have also been captured in this market report, arranged in alphabetical order) include Aardex, Clariness, Cliniv Health Tech, CMIC, DynamiQ Health, Flatworld Solutions, Fortrea, Futuremeds, Gsap, Hexaware Technologies, Huma, ICON, IQVIA, Kayentis, KORE Wireless, Medidata Solutions, Medpace, Parexel, PPD (a Thermo Fisher Company), Signant Health, Syneos Health, Tata Consultancy Services, Veeva, Viedoc, WeGuide, Wren Healthcare and Zealth.

Market Segmentation Insights

Frequently Asked Questions